Edimer Pharmaceuticals' Series B Round

Edimer Pharmaceuticals raised a round of funding on July 30, 2013.

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including…

Articles about Edimer Pharmaceuticals' Series B Round: